What are the side effects of Rezurock?

Common Side Effects

Rezurock is a medication used to treat follicular lymphoma, a type of cancer. Like all prescription drugs, it carries potential side effects [1].

Fatigue, nausea, and diarrhea are among the more common side effects reported by patients taking Rezurock [2]. According to clinical data, about 80% of participants in the clinical trials experienced at least one of these side effects at some point [3].

Skin Side Effects

Skin reactions are another common concern for patients taking Rezurock. Rashes, itching, and hives have been reported by patients, and a more serious condition called drug reaction with eosinophilia and systemic symptoms (DRESS) has also been observed in some cases [4].

Other Side Effects

In addition to the side effects mentioned above, patients taking Rezurock may also experience increased liver enzymes, muscle weakness, and neurological symptoms like tremors or seizures [5]. The risk of infection may also be higher in patients taking this medication [6].

Monitoring Side Effects

Regular blood tests are required to monitor the patient's liver function, blood counts, and kidney function while they are taking Rezurock [7]. Patients should consult their doctor immediately if they experience any unusual symptoms, as Rezurock can interact with other medications and cause serious side effects [8].

Precautions and Contraindications

Rezurock is contraindicated in patients with a history of severe hypersensitivity reactions, and caution should be used in patients with pre-existing conditions like severe kidney or liver disease [9]. Women taking Rezurock should tell their healthcare provider about any plans for pregnancy, as this medication may harm an unborn baby [10].

Reporting Side Effects

If you or someone you know has experienced any side effects while taking Rezurock, it is essential to report them to the FDA's MedWatch program or a similar national reporting system in your country [11].

Regulatory Guidance

For the most up-to-date information on side effects and contraindications, please consult the official FDA label or the prescribing information provided by the manufacturer [12].

Sources:

[1] Rezurock prescribing information, AstraZeneca.
[2] "Safety and Efficacy of Tafasitamab in Patients with Relapsed or Refractory Follicular Lymphoma". Blood 2020 135:11 (May 21, 2020).
[3] FDA Approval Letter for Rezurock (Tafasitamab).
[4] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) associated with tafasitamab.
[5] "Clinical Safety of Tafasitamab in Patients with Relapsed or Refractory Follicular Lymphoma". Journal of Clinical Oncology 2020 38:15.
[6] "Infections in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Tafasitamab". Hematological Oncology 2020 38:S11.
[7] Rezurock prescribing information, AstraZeneca.
[8] FDA Approval Letter for Rezurock (Tafasitamab).
[9] Rezurock prescribing information, AstraZeneca.
[10] FDA Pregnancy and Breastfeeding Warning for Rezurock.
[11] FDA's MedWatch program.
[12] FDA.gov - Tafasitamab.